Physician profile
Megan E Hall
NPI 1144793613
$4,803.86
in general payments reported to CMS, 2019-2025
22 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,309 · 2022: $1,559 · 2023: $1,410 · 2024: $243 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Education: $54.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.60 |
| Education | $54.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $789.41 | 2021-2025 | Jynarque |
| Amgen INC. | $736.01 | 2021-2023 | Tavneos |
| Vifor Pharma, INC. | $608.91 | 2021-2023 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $431.86 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $358.64 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $296.52 | 2021-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $296.22 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $248.02 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $232.17 | 2022-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $162.42 | 2022-2025 | Tarpeyo |
| Arbor Pharmaceuticals, INC. | $139.42 | 2021 | |
| Atricure, INC. | $85.92 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.83 | 2022-2023 | Jardiance |
| Travere Therapeutics, INC. | $79.78 | 2023-2024 | |
| Horizon Therapeutics Plc | $74.47 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $55.73 | 2021-2025 | Ultomiris |
| Recordati_rare_diseases_inc. | $27.75 | 2021 | |
| Lilly USA, LLC | $23.32 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $19.31 | 2021 | |
| Novo Nordisk INC | $18.83 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.59 | 2023 | Jynarque |
| Akebia Therapeutics INC | $15.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.